Loading...
•
Jun 30, 2022
Amneal Q2 2022 Earnings Report
Solid results reflected topline growth across all three segments and meaningful acceleration in performance from the first quarter.
Key Takeaways
Amneal Pharmaceuticals reported net revenue of $559 million, a 5% increase compared to Q2 2021. The company experienced a net loss of $121 million, which included a pre-tax charge of $263 million related to the Opana ER® antitrust litigation settlement. Adjusted EBITDA was $135 million, a 6% decrease compared to the previous year, while adjusted diluted EPS was $0.19, down from $0.23 in Q2 2021.
Net revenue increased by 5% to $559 million compared to Q2 2021.
Net loss attributable to Amneal Pharmaceuticals was $121 million, compared to net income of $15 million in Q2 2021, impacted by a $263 million charge for the Opana ER® antitrust litigation settlement.
Adjusted EBITDA decreased by 6% to $135 million compared to Q2 2021.
Diluted loss per share was $(0.80), and adjusted diluted EPS was $0.19, compared to $0.10 and $0.23, respectively, in Q2 2021.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
The Company is updating its full year 2022 guidance. Revised Full Year 2022 GuidancePrior Full Year 2022 GuidanceNet revenue$2.15 billion - $2.25 billion$2.15 billion - $2.25 billionAdjusted EBITDA (1)$500 million - $520 million$540 million - $560 millionAdjusted diluted EPS (2)$0.65 - $0.70$0.80 - $0.85Operating cash flow (3)$200 million - $225 million$225 million - $250 millionCapital expenditures$65 million - $75 million$75 million - $85 millionWeighted average diluted shares outstanding (4)Approximately 305 millionApproximately 307 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income